Head-to-head evidence
entacapone vs Trigel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: COMT · full Parkinson's Disease pipeline
entacapone · Comtess
Marketed by Orion Corporation
NCT00099268 · Phase 3 · completed
The trial was randomized, quadruple-blind, actively controlled, and included 747 participants, with a clinical primary endpoint measuring time to first dyskinesia. However, the reported numerical result favored the comparator, and no p-value or other statistical comparison is provided, so the primary endpoint cannot be classified as definitively met or missed.
Next expected readout: February 2027 · NCT04246437 (registry estimate)
Trigel · Lecigon
Developed by LobSor Pharmaceuticals AB and partners
NCT02448914 · Phase 1 · completed
This trial had randomized treatment order and an active comparator, and it reached a statistically significant result for its primary measure, but it was not blinded, enrolled only 11 patients, and measured drug blood levels rather than a clinical symptom or functional outcome, so it demonstrates pharmacokinetic exposure rather than a proven clinical benefit.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Trigel's landscape